calpain inhibitor 2 has been researched along with 25-hydroxycholesterol in 1 studies
| Studies (calpain inhibitor 2) | Trials (calpain inhibitor 2) | Recent Studies (post-2010) (calpain inhibitor 2) | Studies (25-hydroxycholesterol) | Trials (25-hydroxycholesterol) | Recent Studies (post-2010) (25-hydroxycholesterol) |
|---|---|---|---|---|---|
| 68 | 0 | 13 | 853 | 3 | 243 |
| Protein | Taxonomy | calpain inhibitor 2 (IC50) | 25-hydroxycholesterol (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.3 | |
| Sterol regulatory element-binding protein 2 | Homo sapiens (human) | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avner, R; Doolman, R; Harats, D; Ravid, T; Roitelman, J | 1 |
1 other study(ies) available for calpain inhibitor 2 and 25-hydroxycholesterol
| Article | Year |
|---|---|
The ubiquitin-proteasome pathway mediates the regulated degradation of mammalian 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Topics: Animals; beta-Galactosidase; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Cholesterol; Cricetinae; Cycloheximide; Cysteine Proteinase Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Leupeptins; Lovastatin; Oligopeptides; Peptide Hydrolases; Precipitin Tests; Proteasome Endopeptidase Complex; Recombinant Fusion Proteins; Tricarboxylic Acids; Ubiquitins | 2000 |